Nara Prefectural Health Research Center, Nara Medical University.
Chuwa Public Health Center of Nara Prefectural Government.
Environ Health Prev Med. 2023;28:7. doi: 10.1265/ehpm.22-00199.
Many previous studies have reported COVID-19 vaccine effectiveness, but there are few studies in Japan. This community-based, retrospective observational study investigated the association between vaccination status and COVID-19-related health outcomes in COVID-19 patients by SARS-CoV-2 variant type.
The study participants were 24,314 COVID-19 patients aged 12 or older whose diagnoses were reported to the Nara Prefecture Chuwa Public Health Center from April 2021 to March 2022, during periods when the alpha, delta, and omicron variants of COVID-19 were predominant. The outcome variables were severe health consequences (SHC) (i.e., ICU admission and COVID-19-related death), hospitalization, and extension of recovery period. The explanatory variable was vaccination status at least 14 days prior to infection. Covariates included gender, age, population size, the number of risk factors for aggravation, and the number of symptoms at diagnosis. The generalized estimating equations of the multivariable Poisson regression models were used to estimate the adjusted incidence proportion (AIP) and 95% confidence interval (CI) for each health outcome. We performed stratified analyses by SARS-CoV-2 variant type, but the association between vaccination status and COVID-19-related health outcomes was stratified only for the delta and omicron variants due to the small number of vaccinated patients during the alpha variant.
Of the 24,314 participants, 255 (1.0%) had SHC; of the 24,059 participants without SHC, 2,102 (8.7%) were hospitalized; and of the 19,603 participants without SHC, hospitalization, and missing data on recovery period, 2,960 (15.1%) had extension of recovery period. Multivariable Poisson regression models showed that regardless of SARS-CoV-2 variant type or health outcome, those who received two or more vaccine doses had significantly lower risk of health outcomes than those who did not receive the vaccine, and there was a dose-response relationship in which the AIP for health outcomes decreased with an increased number of vaccinations.
A higher number of vaccinations were associated with lower risk of COVID-19-related health outcomes, not only in the delta variant but also in the omicron variant. Our findings suggest that increasing the number of COVID-19 vaccine doses can prevent severe disease and lead to early recovery of patients not requiring hospitalization.
许多先前的研究报告了 COVID-19 疫苗的有效性,但日本的研究较少。本基于社区的回顾性观察研究通过 SARS-CoV-2 变体类型调查了疫苗接种状态与 COVID-19 患者相关健康结果之间的关联。
本研究的参与者是 2021 年 4 月至 2022 年 3 月期间向奈良县中川公共卫生中心报告诊断的 24314 名 12 岁及以上的 COVID-19 患者,在此期间,COVID-19 的 alpha、delta 和 omicron 变体占主导地位。结局变量是严重健康后果(SHC)(即 ICU 入院和 COVID-19 相关死亡)、住院和康复期延长。解释变量是感染前至少 14 天的疫苗接种状态。协变量包括性别、年龄、人口规模、加重风险因素的数量和诊断时的症状数量。多变量泊松回归模型的广义估计方程用于估计每个健康结果的调整发病率比例(AIP)和 95%置信区间(CI)。我们按 SARS-CoV-2 变体类型进行分层分析,但由于 alpha 变体期间接种疫苗的患者人数较少,仅对 delta 和 omicron 变体进行了疫苗接种状态与 COVID-19 相关健康结果之间的分层分析。
在 24314 名参与者中,有 255 名(1.0%)发生 SHC;在 24059 名无 SHC 的参与者中,有 2102 名(8.7%)住院;在 19603 名无 SHC、住院和康复期缺失数据的参与者中,有 2960 名(15.1%)康复期延长。多变量泊松回归模型显示,无论 SARS-CoV-2 变体类型或健康结果如何,接种两剂或更多疫苗的人发生健康结果的风险明显低于未接种疫苗的人,并且存在剂量反应关系,即健康结果的 AIP 随着接种疫苗数量的增加而降低。
接种疫苗的数量越多,与 COVID-19 相关的健康结果的风险越低,不仅在 delta 变体中,而且在 omicron 变体中也是如此。我们的研究结果表明,增加 COVID-19 疫苗接种剂量可以预防重症疾病并导致不需要住院的患者早日康复。